Video

Dr. Postow on Combination Regimens for High-Risk Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combinations of regimens for patients with high-risk melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combinations of regimens for patients with high-risk melanoma.

There was the first data regarding the BRAF and MEK inhibitors, dabrafenib (Tafinlar) and tremetinib (Mekinst), against observation in the COMBI-AD study. There are also randomized data for adjuvant nivolumab (Opdivo) versus adjuvant ipilimumab (Yervoy) in the CheckMate-238 study.

These data were highly anticipated since these regimens are effective for stage IV or unresectable stage III patients with melanoma, but this is the first time that researchers are seeing definitive data about the efficacy of these drugs in patients who have had surgically resected high-risk melanoma, explains Postow.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Binod Dhakal, MD
Sheldon M. Feldman, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.